JP2020510065A - 抗がん化合物 - Google Patents
抗がん化合物 Download PDFInfo
- Publication number
- JP2020510065A JP2020510065A JP2019550649A JP2019550649A JP2020510065A JP 2020510065 A JP2020510065 A JP 2020510065A JP 2019550649 A JP2019550649 A JP 2019550649A JP 2019550649 A JP2019550649 A JP 2019550649A JP 2020510065 A JP2020510065 A JP 2020510065A
- Authority
- JP
- Japan
- Prior art keywords
- unsubstituted
- substituted
- compound
- hydrogen
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 123
- 230000001093 anti-cancer Effects 0.000 title abstract description 5
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 20
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 16
- 201000011510 cancer Diseases 0.000 claims abstract description 14
- 238000004519 manufacturing process Methods 0.000 claims abstract description 13
- 229910052739 hydrogen Inorganic materials 0.000 claims description 44
- 108090000623 proteins and genes Proteins 0.000 claims description 44
- 239000001257 hydrogen Substances 0.000 claims description 43
- 150000003839 salts Chemical class 0.000 claims description 40
- 210000004027 cell Anatomy 0.000 claims description 39
- 125000000217 alkyl group Chemical group 0.000 claims description 34
- 238000000034 method Methods 0.000 claims description 29
- 102000004169 proteins and genes Human genes 0.000 claims description 28
- 150000007523 nucleic acids Chemical class 0.000 claims description 27
- 108091008053 gene clusters Proteins 0.000 claims description 24
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 22
- 150000002431 hydrogen Chemical class 0.000 claims description 21
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 21
- 125000003118 aryl group Chemical group 0.000 claims description 20
- 229940125904 compound 1 Drugs 0.000 claims description 19
- 125000006710 (C2-C12) alkenyl group Chemical group 0.000 claims description 18
- 125000006711 (C2-C12) alkynyl group Chemical group 0.000 claims description 18
- 239000000203 mixture Substances 0.000 claims description 16
- 229940125782 compound 2 Drugs 0.000 claims description 15
- 125000000623 heterocyclic group Chemical group 0.000 claims description 15
- 108020004707 nucleic acids Proteins 0.000 claims description 15
- 102000039446 nucleic acids Human genes 0.000 claims description 15
- 230000001851 biosynthetic effect Effects 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 11
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 10
- 239000002773 nucleotide Substances 0.000 claims description 10
- 125000003729 nucleotide group Chemical group 0.000 claims description 10
- 230000001580 bacterial effect Effects 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 9
- 230000000295 complement effect Effects 0.000 claims description 8
- 102000004190 Enzymes Human genes 0.000 claims description 7
- 108090000790 Enzymes Proteins 0.000 claims description 7
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 7
- 238000003786 synthesis reaction Methods 0.000 claims description 7
- 238000012258 culturing Methods 0.000 claims description 6
- 230000009261 transgenic effect Effects 0.000 claims description 6
- 229930001118 polyketide hybrid Natural products 0.000 claims description 4
- 125000003308 polyketide hybrid group Chemical group 0.000 claims description 4
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 241000589291 Acinetobacter Species 0.000 claims description 2
- 241000193830 Bacillus <bacterium> Species 0.000 claims description 2
- 241000588724 Escherichia coli Species 0.000 claims description 2
- 241000589516 Pseudomonas Species 0.000 claims description 2
- 241000187747 Streptomyces Species 0.000 claims description 2
- 230000005714 functional activity Effects 0.000 claims description 2
- 125000000830 polyketide group Chemical group 0.000 claims description 2
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims 2
- 101150017124 lab gene Proteins 0.000 abstract description 7
- 101100386054 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) CYS3 gene Proteins 0.000 abstract 1
- 101150035983 str1 gene Proteins 0.000 abstract 1
- -1 8-quinolyl Quinolyl Chemical group 0.000 description 184
- 235000002639 sodium chloride Nutrition 0.000 description 36
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 30
- 125000006239 protecting group Chemical group 0.000 description 30
- ZNEZZONMADKYTB-VRCUBXEUSA-N pederin Chemical compound C1[C@@H](O)C(C)(C)[C@@H](C[C@@H](COC)OC)O[C@@H]1[C@H](OC)NC(=O)[C@@H](O)[C@]1(OC)O[C@H](C)[C@H](C)C(=C)C1 ZNEZZONMADKYTB-VRCUBXEUSA-N 0.000 description 28
- MHRARRIFWSILEQ-UHFFFAOYSA-N Pederin Natural products COCC(CC1OC2C(NC(=O)C(O)C3(CC(=O)C(C)C(C)O3)OC)OCOC2C(OC)C1(C)C)OC MHRARRIFWSILEQ-UHFFFAOYSA-N 0.000 description 26
- 108010030975 Polyketide Synthases Proteins 0.000 description 21
- 241000894006 Bacteria Species 0.000 description 14
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 12
- 150000000180 1,2-diols Chemical class 0.000 description 11
- 108020004465 16S ribosomal RNA Proteins 0.000 description 10
- 238000002955 isolation Methods 0.000 description 10
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 10
- YWUNVHXKGMPHDM-AMTQNMNTSA-N (2s)-2-[[(2e,4e,6e,11r)-12-[(4s,4as,6r,8s,8ar)-4-[[(2s)-2-hydroxy-2-[(2r,5r,6r)-2-methoxy-5,6-dimethyl-4-methylideneoxan-2-yl]acetyl]amino]-8-methoxy-7,7-dimethyl-4a,6,8,8a-tetrahydro-4h-pyrano[3,2-d][1,3]dioxin-6-yl]-11-hydroxydodeca-2,4,6-trienoyl]amino Chemical compound CO[C@]1([C@H](O)C(=O)N[C@H]2OCO[C@@H]3[C@H](C([C@@H](C[C@H](O)CCC\C=C\C=C\C=C\C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)O[C@@H]32)(C)C)OC)CC(=C)[C@@H](C)[C@@H](C)O1 YWUNVHXKGMPHDM-AMTQNMNTSA-N 0.000 description 9
- 101000979117 Curvularia clavata Nonribosomal peptide synthetase Proteins 0.000 description 9
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 230000001472 cytotoxic effect Effects 0.000 description 9
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 9
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 9
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 9
- 239000002609 medium Substances 0.000 description 9
- 229930194314 onnamide Natural products 0.000 description 9
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 9
- 239000011734 sodium Substances 0.000 description 8
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical class OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 7
- 150000001241 acetals Chemical class 0.000 description 7
- 238000000855 fermentation Methods 0.000 description 7
- 230000004151 fermentation Effects 0.000 description 7
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 7
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 6
- 230000000259 anti-tumor effect Effects 0.000 description 6
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 6
- 125000004432 carbon atom Chemical group C* 0.000 description 6
- 125000004122 cyclic group Chemical group 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 125000001424 substituent group Chemical group 0.000 description 6
- IOOMXAQUNPWDLL-UHFFFAOYSA-N 2-[6-(diethylamino)-3-(diethyliminiumyl)-3h-xanthen-9-yl]-5-sulfobenzene-1-sulfonate Chemical compound C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=C(S(O)(=O)=O)C=C1S([O-])(=O)=O IOOMXAQUNPWDLL-UHFFFAOYSA-N 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
- 238000005481 NMR spectroscopy Methods 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 238000001802 infusion Methods 0.000 description 5
- 125000004430 oxygen atom Chemical group O* 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 238000001228 spectrum Methods 0.000 description 5
- 230000002194 synthesizing effect Effects 0.000 description 5
- HEVMDQBCAHEHDY-UHFFFAOYSA-N (Dimethoxymethyl)benzene Chemical compound COC(OC)C1=CC=CC=C1 HEVMDQBCAHEHDY-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 239000007983 Tris buffer Substances 0.000 description 4
- 125000003342 alkenyl group Chemical group 0.000 description 4
- 125000000304 alkynyl group Chemical group 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000007621 cluster analysis Methods 0.000 description 4
- YPHMISFOHDHNIV-FSZOTQKASA-N cycloheximide Chemical compound C1[C@@H](C)C[C@H](C)C(=O)[C@@H]1[C@H](O)CC1CC(=O)NC(=O)C1 YPHMISFOHDHNIV-FSZOTQKASA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 235000019439 ethyl acetate Nutrition 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 239000002054 inoculum Substances 0.000 description 4
- 239000006325 marine broth Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 4
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
- DDCPKNYKNWXULB-RXMQYKEDSA-N (2r)-2-azaniumyl-3-[(2-methylpropan-2-yl)oxy]propanoate Chemical compound CC(C)(C)OC[C@@H]([NH3+])C([O-])=O DDCPKNYKNWXULB-RXMQYKEDSA-N 0.000 description 3
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 101710146995 Acyl carrier protein Proteins 0.000 description 3
- 108010058912 Acyl-Carrier Protein S-Malonyltransferase Proteins 0.000 description 3
- 102000006488 Acyl-Carrier Protein S-Malonyltransferase Human genes 0.000 description 3
- 241000526125 Diaphorina citri Species 0.000 description 3
- 102000011426 Enoyl-CoA hydratase Human genes 0.000 description 3
- 108010023922 Enoyl-CoA hydratase Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 108090000854 Oxidoreductases Proteins 0.000 description 3
- 102000004316 Oxidoreductases Human genes 0.000 description 3
- 241000243142 Porifera Species 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 description 3
- 230000006154 adenylylation Effects 0.000 description 3
- 230000000840 anti-viral effect Effects 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 239000000287 crude extract Substances 0.000 description 3
- 150000005676 cyclic carbonates Chemical class 0.000 description 3
- 231100000433 cytotoxic Toxicity 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- UREBWPXBXRYXRJ-UHFFFAOYSA-N ethyl acetate;methanol Chemical compound OC.CCOC(C)=O UREBWPXBXRYXRJ-UHFFFAOYSA-N 0.000 description 3
- 238000003818 flash chromatography Methods 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 125000001072 heteroaryl group Chemical group 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 230000001035 methylating effect Effects 0.000 description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- 229940049953 phenylacetate Drugs 0.000 description 3
- 125000006413 ring segment Chemical group 0.000 description 3
- 239000013049 sediment Substances 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000006257 total synthesis reaction Methods 0.000 description 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- MCIPQLOKVXSHTD-UHFFFAOYSA-N 3,3-diethoxyprop-1-ene Chemical compound CCOC(C=C)OCC MCIPQLOKVXSHTD-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- JOOXCMJARBKPKM-UHFFFAOYSA-M 4-oxopentanoate Chemical compound CC(=O)CCC([O-])=O JOOXCMJARBKPKM-UHFFFAOYSA-M 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 101710186015 Acetyltransferase Pat Proteins 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 239000002028 Biomass Substances 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 2
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 101710116650 FAD-dependent monooxygenase Proteins 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 229910002651 NO3 Inorganic materials 0.000 description 2
- 101150109417 NRPS gene Proteins 0.000 description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 2
- 101710128228 O-methyltransferase Proteins 0.000 description 2
- GKBXVDCZBLUPLU-UHFFFAOYSA-N Onnamide A Natural products COC1C2OCOC(NC(=O)C(O)C3(CC(=O)C(C)C(C)O3)OC)C2OC(CC(O)CCCC=CC=CC=CC(=O)NC(CCCNC(=N)N)C(=O)O)C1(C)C GKBXVDCZBLUPLU-UHFFFAOYSA-N 0.000 description 2
- DOERNKDPZZWHPM-UHFFFAOYSA-N Onnamide F Natural products C1C(OC)C(C)(C)C(CC(O)CCCC=CC=CC(O)=O)OC1C(OC)NC(=O)C(O)C1(OC)CC(=C)C(C)C(C)O1 DOERNKDPZZWHPM-UHFFFAOYSA-N 0.000 description 2
- 108090000417 Oxygenases Proteins 0.000 description 2
- 102000004020 Oxygenases Human genes 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- COQLPRJCUIATTQ-UHFFFAOYSA-N Uranyl acetate Chemical compound O.O.O=[U]=O.CC(O)=O.CC(O)=O COQLPRJCUIATTQ-UHFFFAOYSA-N 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- GZUXJHMPEANEGY-UHFFFAOYSA-N bromomethane Chemical compound BrC GZUXJHMPEANEGY-UHFFFAOYSA-N 0.000 description 2
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 238000007398 colorimetric assay Methods 0.000 description 2
- 239000012230 colorless oil Substances 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- LPIQUOYDBNQMRZ-UHFFFAOYSA-N cyclopentene Chemical compound C1CC=CC1 LPIQUOYDBNQMRZ-UHFFFAOYSA-N 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical class C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 238000001493 electron microscopy Methods 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 230000008029 eradication Effects 0.000 description 2
- 150000002170 ethers Chemical class 0.000 description 2
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000004896 high resolution mass spectrometry Methods 0.000 description 2
- 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- AUHZEENZYGFFBQ-UHFFFAOYSA-N mesitylene Substances CC1=CC(C)=CC(C)=C1 AUHZEENZYGFFBQ-UHFFFAOYSA-N 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 2
- 239000003471 mutagenic agent Substances 0.000 description 2
- 231100000707 mutagenic chemical Toxicity 0.000 description 2
- 230000003505 mutagenic effect Effects 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- DOERNKDPZZWHPM-CCLUXEDBSA-N onnamide f Chemical compound CO[C@]1([C@H](O)C(=O)N[C@@H](OC)[C@H]2O[C@H](CC(O)CCC\C=C\C=C\C(O)=O)C(C)(C)[C@H](OC)C2)CC(=C)[C@@H](C)[C@@H](C)O1 DOERNKDPZZWHPM-CCLUXEDBSA-N 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- LCPDWSOZIOUXRV-UHFFFAOYSA-N phenoxyacetic acid Chemical compound OC(=O)COC1=CC=CC=C1 LCPDWSOZIOUXRV-UHFFFAOYSA-N 0.000 description 2
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 238000001896 rotating frame Overhauser effect spectroscopy Methods 0.000 description 2
- 238000013341 scale-up Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000011894 semi-preparative HPLC Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 2
- 150000003871 sulfonates Chemical class 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 125000004434 sulfur atom Chemical group 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000009897 systematic effect Effects 0.000 description 2
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 2
- 238000001269 time-of-flight mass spectrometry Methods 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 229940066528 trichloroacetate Drugs 0.000 description 2
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 2
- 125000000025 triisopropylsilyl group Chemical group C(C)(C)[Si](C(C)C)(C(C)C)* 0.000 description 2
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- NFLGAXVYCFJBMK-BDAKNGLRSA-N (-)-menthone Chemical compound CC(C)[C@@H]1CC[C@@H](C)CC1=O NFLGAXVYCFJBMK-BDAKNGLRSA-N 0.000 description 1
- YASHSAMOKSQSHZ-UHFFFAOYSA-N (1,1,1-trichloro-2-methylpropan-2-yl) hydrogen carbonate Chemical compound ClC(Cl)(Cl)C(C)(C)OC(O)=O YASHSAMOKSQSHZ-UHFFFAOYSA-N 0.000 description 1
- ZORNQOZBHTYERW-UHFFFAOYSA-N (2-amino-1-phenylethyl) hydrogen carbonate Chemical compound OC(=O)OC(CN)C1=CC=CC=C1 ZORNQOZBHTYERW-UHFFFAOYSA-N 0.000 description 1
- TYMGRSZMTKMZNT-UHFFFAOYSA-N (2-cyano-1-phenylethyl) hydrogen carbonate Chemical compound OC(=O)OC(CC#N)C1=CC=CC=C1 TYMGRSZMTKMZNT-UHFFFAOYSA-N 0.000 description 1
- PMIODTBPFKLUMF-UHFFFAOYSA-N (2-nitrophenyl)methyl hydrogen carbonate Chemical compound OC(=O)OCC1=CC=CC=C1[N+]([O-])=O PMIODTBPFKLUMF-UHFFFAOYSA-N 0.000 description 1
- JDDUQGRUPLKDNT-IDTAVKCVSA-N (2r,3r,4s,5s)-2-(6-aminopurin-9-yl)-5-(2-methylpropylsulfanylmethyl)oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CSCC(C)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 JDDUQGRUPLKDNT-IDTAVKCVSA-N 0.000 description 1
- NNNVJFAPLNIYPF-FQZCGRDXSA-N (2s)-n-[(s)-[(2s,4r,6r)-6-[(2s)-2,3-dimethoxypropyl]-4-hydroxy-5,5-dimethyloxan-2-yl]-methoxymethyl]-2-hydroxy-2-[(2r,5r,6r)-2-hydroxy-5,6-dimethyl-4-methylideneoxan-2-yl]acetamide Chemical compound C1[C@@H](O)C(C)(C)[C@@H](C[C@@H](COC)OC)O[C@@H]1[C@H](OC)NC(=O)[C@@H](O)[C@]1(O)O[C@H](C)[C@H](C)C(=C)C1 NNNVJFAPLNIYPF-FQZCGRDXSA-N 0.000 description 1
- ZTESKPLFUKCHOF-UHFFFAOYSA-N (3,4-dimethoxyphenyl)methyl hydrogen carbonate Chemical compound COC1=CC=C(COC(O)=O)C=C1OC ZTESKPLFUKCHOF-UHFFFAOYSA-N 0.000 description 1
- SODPIMGUZLOIPE-UHFFFAOYSA-N (4-chlorophenoxy)acetic acid Chemical compound OC(=O)COC1=CC=C(Cl)C=C1 SODPIMGUZLOIPE-UHFFFAOYSA-N 0.000 description 1
- ISZJQQWIYSBXLV-UHFFFAOYSA-N (4-chlorophenyl) hydrogen carbonate Chemical compound OC(=O)OC1=CC=C(Cl)C=C1 ISZJQQWIYSBXLV-UHFFFAOYSA-N 0.000 description 1
- ZGDWQQIXRCQCLZ-UHFFFAOYSA-N (4-ethoxynaphthalen-1-yl) hydrogen carbonate Chemical compound C1=CC=C2C(OCC)=CC=C(OC(O)=O)C2=C1 ZGDWQQIXRCQCLZ-UHFFFAOYSA-N 0.000 description 1
- HZFLPRPFCHEBPQ-UHFFFAOYSA-N (4-methoxyphenyl)methyl hydrogen carbonate Chemical compound COC1=CC=C(COC(O)=O)C=C1 HZFLPRPFCHEBPQ-UHFFFAOYSA-N 0.000 description 1
- QZHJCWDHTISLNN-UHFFFAOYSA-N (6-bromo-7-hydroxy-2-oxochromen-4-yl) methyl carbonate Chemical compound C(OC1=CC(OC2=CC(=C(C=C12)Br)O)=O)(OC)=O QZHJCWDHTISLNN-UHFFFAOYSA-N 0.000 description 1
- YRUGXUSOGGCHAF-UHFFFAOYSA-N (9,10-dioxoanthracen-2-yl)methyl hydrogen carbonate Chemical compound C1=CC=C2C(=O)C3=CC(COC(=O)O)=CC=C3C(=O)C2=C1 YRUGXUSOGGCHAF-UHFFFAOYSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- ZOJKRWXDNYZASL-NSCUHMNNSA-N (e)-4-methoxybut-2-enoic acid Chemical compound COC\C=C\C(O)=O ZOJKRWXDNYZASL-NSCUHMNNSA-N 0.000 description 1
- 125000005943 1,2,3,6-tetrahydropyridyl group Chemical group 0.000 description 1
- 125000000424 1,2-diol group Chemical group 0.000 description 1
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical group C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 description 1
- JPRPJUMQRZTTED-UHFFFAOYSA-N 1,3-dioxolanyl Chemical group [CH]1OCCO1 JPRPJUMQRZTTED-UHFFFAOYSA-N 0.000 description 1
- MNCMBBIFTVWHIP-UHFFFAOYSA-N 1-anthracen-9-yl-2,2,2-trifluoroethanone Chemical group C1=CC=C2C(C(=O)C(F)(F)F)=C(C=CC=C3)C3=CC2=C1 MNCMBBIFTVWHIP-UHFFFAOYSA-N 0.000 description 1
- LNETULKMXZVUST-UHFFFAOYSA-N 1-naphthoic acid Chemical compound C1=CC=C2C(C(=O)O)=CC=CC2=C1 LNETULKMXZVUST-UHFFFAOYSA-N 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- ICVJPGVOKHLFGW-UHFFFAOYSA-N 190004115174 Chemical compound COBO ICVJPGVOKHLFGW-UHFFFAOYSA-N 0.000 description 1
- 125000000453 2,2,2-trichloroethyl group Chemical group [H]C([H])(*)C(Cl)(Cl)Cl 0.000 description 1
- PYHXGXCGESYPCW-UHFFFAOYSA-M 2,2-diphenylacetate Chemical compound C=1C=CC=CC=1C(C(=O)[O-])C1=CC=CC=C1 PYHXGXCGESYPCW-UHFFFAOYSA-M 0.000 description 1
- FFFIRKXTFQCCKJ-UHFFFAOYSA-M 2,4,6-trimethylbenzoate Chemical compound CC1=CC(C)=C(C([O-])=O)C(C)=C1 FFFIRKXTFQCCKJ-UHFFFAOYSA-M 0.000 description 1
- 125000001917 2,4-dinitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C(=C1*)[N+]([O-])=O)[N+]([O-])=O 0.000 description 1
- LBQMIAVIGLLBGW-UHFFFAOYSA-M 2,5-difluorobenzoate Chemical compound [O-]C(=O)C1=CC(F)=CC=C1F LBQMIAVIGLLBGW-UHFFFAOYSA-M 0.000 description 1
- 125000006508 2,6-difluorobenzyl group Chemical group [H]C1=C([H])C(F)=C(C(F)=C1[H])C([H])([H])* 0.000 description 1
- YURLCYGZYWDCHL-UHFFFAOYSA-N 2-(2,6-dichloro-4-methylphenoxy)acetic acid Chemical compound CC1=CC(Cl)=C(OCC(O)=O)C(Cl)=C1 YURLCYGZYWDCHL-UHFFFAOYSA-N 0.000 description 1
- IXSGUIFSMPTAGW-UHFFFAOYSA-N 2-(trifluoromethyl)benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1C(F)(F)F IXSGUIFSMPTAGW-UHFFFAOYSA-N 0.000 description 1
- 125000003821 2-(trimethylsilyl)ethoxymethyl group Chemical group [H]C([H])([H])[Si](C([H])([H])[H])(C([H])([H])[H])C([H])([H])C(OC([H])([H])[*])([H])[H] 0.000 description 1
- IZQAUUVBKYXMET-UHFFFAOYSA-N 2-bromoethanamine Chemical compound NCCBr IZQAUUVBKYXMET-UHFFFAOYSA-N 0.000 description 1
- 125000005999 2-bromoethyl group Chemical group 0.000 description 1
- UJRMHFPTLFNSTA-UHFFFAOYSA-N 2-chloro-2,2-diphenylacetic acid Chemical compound C=1C=CC=CC=1C(Cl)(C(=O)O)C1=CC=CC=C1 UJRMHFPTLFNSTA-UHFFFAOYSA-N 0.000 description 1
- IKCLCGXPQILATA-UHFFFAOYSA-M 2-chlorobenzoate Chemical compound [O-]C(=O)C1=CC=CC=C1Cl IKCLCGXPQILATA-UHFFFAOYSA-M 0.000 description 1
- SHHKMWMIKILKQW-UHFFFAOYSA-M 2-formylbenzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1C=O SHHKMWMIKILKQW-UHFFFAOYSA-M 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- CJNZAXGUTKBIHP-UHFFFAOYSA-M 2-iodobenzoate Chemical compound [O-]C(=O)C1=CC=CC=C1I CJNZAXGUTKBIHP-UHFFFAOYSA-M 0.000 description 1
- JWHHNSIZTDYRCL-UHFFFAOYSA-N 2-methylbutan-2-yl 2-phenoxyacetate Chemical compound CCC(C)(C)OC(=O)COC1=CC=CC=C1 JWHHNSIZTDYRCL-UHFFFAOYSA-N 0.000 description 1
- WTLKTXIHIHFSGU-UHFFFAOYSA-N 2-nitrosoguanidine Chemical compound NC(N)=NN=O WTLKTXIHIHFSGU-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000006494 2-trifluoromethyl benzyl group Chemical group [H]C1=C([H])C([H])=C(C(=C1[H])C([H])([H])*)C(F)(F)F 0.000 description 1
- GPVOTFQILZVCFP-UHFFFAOYSA-N 2-trityloxyacetic acid Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(OCC(=O)O)C1=CC=CC=C1 GPVOTFQILZVCFP-UHFFFAOYSA-N 0.000 description 1
- 125000001698 2H-pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000002774 3,4-dimethoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C(OC([H])([H])[H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 1
- 108010019608 3-Oxoacyl-(Acyl-Carrier-Protein) Synthase Proteins 0.000 description 1
- UIZRYODUASPRQB-UHFFFAOYSA-M 3-phenylprop-2-enyl carbonate Chemical compound [O-]C(=O)OCC=CC1=CC=CC=C1 UIZRYODUASPRQB-UHFFFAOYSA-M 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-M 3-phenylpropionate Chemical compound [O-]C(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-M 0.000 description 1
- BWGRDBSNKQABCB-UHFFFAOYSA-N 4,4-difluoro-N-[3-[3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl]-1-thiophen-2-ylpropyl]cyclohexane-1-carboxamide Chemical compound CC(C)C1=NN=C(C)N1C1CC2CCC(C1)N2CCC(NC(=O)C1CCC(F)(F)CC1)C1=CC=CS1 BWGRDBSNKQABCB-UHFFFAOYSA-N 0.000 description 1
- WAGMYTXJRVPMGW-UHFFFAOYSA-N 4-azidobutanoic acid Chemical compound OC(=O)CCCN=[N+]=[N-] WAGMYTXJRVPMGW-UHFFFAOYSA-N 0.000 description 1
- TUXYZHVUPGXXQG-UHFFFAOYSA-M 4-bromobenzoate Chemical compound [O-]C(=O)C1=CC=C(Br)C=C1 TUXYZHVUPGXXQG-UHFFFAOYSA-M 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- OTLNPYWUJOZPPA-UHFFFAOYSA-M 4-nitrobenzoate Chemical compound [O-]C(=O)C1=CC=C([N+]([O-])=O)C=C1 OTLNPYWUJOZPPA-UHFFFAOYSA-M 0.000 description 1
- NNJMFJSKMRYHSR-UHFFFAOYSA-M 4-phenylbenzoate Chemical compound C1=CC(C(=O)[O-])=CC=C1C1=CC=CC=C1 NNJMFJSKMRYHSR-UHFFFAOYSA-M 0.000 description 1
- 125000001318 4-trifluoromethylbenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])*)C(F)(F)F 0.000 description 1
- 125000001826 4H-pyranyl group Chemical group O1C(=CCC=C1)* 0.000 description 1
- 108010042833 7,8-diaminopelargonic acid aminotransferase Proteins 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 1
- 108700016155 Acyl transferases Proteins 0.000 description 1
- 102000057234 Acyl transferases Human genes 0.000 description 1
- 241001135756 Alphaproteobacteria Species 0.000 description 1
- 108010003118 Bacteriochlorophylls Proteins 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- XHKLONYRPXFMRK-UHFFFAOYSA-N C1(=CC=CC=C1)C(=O)C(O)C1=CC=CC=C1.C(O)(O)=O Chemical compound C1(=CC=CC=C1)C(=O)C(O)C1=CC=CC=C1.C(O)(O)=O XHKLONYRPXFMRK-UHFFFAOYSA-N 0.000 description 1
- QWOJMRHUQHTCJG-UHFFFAOYSA-N CC([CH2-])=O Chemical compound CC([CH2-])=O QWOJMRHUQHTCJG-UHFFFAOYSA-N 0.000 description 1
- ZRVIHIHTDPBEDE-UHFFFAOYSA-N CCOBO Chemical compound CCOBO ZRVIHIHTDPBEDE-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000636398 Candidatus Profftella armatura Species 0.000 description 1
- 244000132059 Carica parviflora Species 0.000 description 1
- 235000014653 Carica parviflora Nutrition 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 229910020366 ClO 4 Inorganic materials 0.000 description 1
- 241000254173 Coleoptera Species 0.000 description 1
- FKLJPTJMIBLJAV-UHFFFAOYSA-N Compound IV Chemical compound O1N=C(C)C=C1CCCCCCCOC1=CC=C(C=2OCCN=2)C=C1 FKLJPTJMIBLJAV-UHFFFAOYSA-N 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical group [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-N Formic acid Chemical group OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 101150056978 HMGS gene Proteins 0.000 description 1
- 102000004867 Hydro-Lyases Human genes 0.000 description 1
- 108090001042 Hydro-Lyases Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 229930194542 Keto Natural products 0.000 description 1
- 241001011861 Labrenzia alexandrii DFL-11 Species 0.000 description 1
- 241000480537 Labrenzia sp. Species 0.000 description 1
- 101001110310 Lentilactobacillus kefiri NADP-dependent (R)-specific alcohol dehydrogenase Proteins 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 102000016397 Methyltransferase Human genes 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- FNJSWIPFHMKRAT-UHFFFAOYSA-N Monomethyl phthalate Chemical compound COC(=O)C1=CC=CC=C1C(O)=O FNJSWIPFHMKRAT-UHFFFAOYSA-N 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241001668559 Mycale Species 0.000 description 1
- GDHIFHFFTOAVPT-UHFFFAOYSA-N N(C(C)=O)C1=CC=CC=C1OBO Chemical compound N(C(C)=O)C1=CC=CC=C1OBO GDHIFHFFTOAVPT-UHFFFAOYSA-N 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000751897 Paederus Species 0.000 description 1
- 241000751898 Paederus fuscipes Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- RHUVSEWLTVNPLK-UHFFFAOYSA-N Pseudopederin Natural products COCC(CC1OC(C(NC(=O)C(O)C2(O)CC(=C)C(C)C(C)O2)OC)C(O)CC1(C)C)OC RHUVSEWLTVNPLK-UHFFFAOYSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 101100011891 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) ERG13 gene Proteins 0.000 description 1
- BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical group [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 description 1
- 241001644136 Stappia Species 0.000 description 1
- 241001521381 Theonella Species 0.000 description 1
- 241001264631 Theonella sp. Species 0.000 description 1
- 241001521370 Theonella swinhoei Species 0.000 description 1
- 102000012463 Thioesterase domains Human genes 0.000 description 1
- 108050002018 Thioesterase domains Proteins 0.000 description 1
- 241001191823 Trachycladus laevispirulifer Species 0.000 description 1
- 108020004566 Transfer RNA Proteins 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical group [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- AMUGPRHQLJDTCE-UHFFFAOYSA-N [1-phenyl-2-(pyridin-2-ylamino)ethyl] hydrogen carbonate Chemical compound C=1C=CC=CC=1C(OC(=O)O)CNC1=CC=CC=N1 AMUGPRHQLJDTCE-UHFFFAOYSA-N 0.000 description 1
- COPSSKKGQYBGGP-UHFFFAOYSA-N [O-]/C(\O)=[S+]\CC1=CC=CC=C1 Chemical compound [O-]/C(\O)=[S+]\CC1=CC=CC=C1 COPSSKKGQYBGGP-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229940022663 acetate Drugs 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 150000004703 alkoxides Chemical class 0.000 description 1
- 150000001347 alkyl bromides Chemical class 0.000 description 1
- 150000001351 alkyl iodides Chemical class 0.000 description 1
- 150000008052 alkyl sulfonates Chemical class 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 125000005336 allyloxy group Chemical group 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001679 anti-nematodal effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- DSJXIQQMORJERS-AGGZHOMASA-M bacteriochlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC([C@H](CC)[C@H]3C)=[N+]4C3=CC3=C(C(C)=O)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 DSJXIQQMORJERS-AGGZHOMASA-M 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004601 benzofurazanyl group Chemical group N1=C2C(=NO1)C(=CC=C2)* 0.000 description 1
- RWCCWEUUXYIKHB-UHFFFAOYSA-N benzophenone Chemical compound C=1C=CC=CC=1C(=O)C1=CC=CC=C1 RWCCWEUUXYIKHB-UHFFFAOYSA-N 0.000 description 1
- 239000012965 benzophenone Substances 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-N beta-phenylpropanoic acid Natural products OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 238000007622 bioinformatic analysis Methods 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- IEPBPSSCIZTJIF-UHFFFAOYSA-N bis(2,2,2-trichloroethyl) carbonate Chemical compound ClC(Cl)(Cl)COC(=O)OCC(Cl)(Cl)Cl IEPBPSSCIZTJIF-UHFFFAOYSA-N 0.000 description 1
- UXXXZMDJQLPQPH-UHFFFAOYSA-N bis(2-methylpropyl) carbonate Chemical compound CC(C)COC(=O)OCC(C)C UXXXZMDJQLPQPH-UHFFFAOYSA-N 0.000 description 1
- ACBQROXDOHKANW-UHFFFAOYSA-N bis(4-nitrophenyl) carbonate Chemical compound C1=CC([N+](=O)[O-])=CC=C1OC(=O)OC1=CC=C([N+]([O-])=O)C=C1 ACBQROXDOHKANW-UHFFFAOYSA-N 0.000 description 1
- JKJWYKGYGWOAHT-UHFFFAOYSA-N bis(prop-2-enyl) carbonate Chemical compound C=CCOC(=O)OCC=C JKJWYKGYGWOAHT-UHFFFAOYSA-N 0.000 description 1
- JZUVESQYEHERMD-UHFFFAOYSA-N bis[(4-nitrophenyl)methyl] carbonate Chemical compound C1=CC([N+](=O)[O-])=CC=C1COC(=O)OCC1=CC=C([N+]([O-])=O)C=C1 JZUVESQYEHERMD-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- XFEIRVZQVUQECX-UHFFFAOYSA-N bromo ethyl carbonate Chemical compound CCOC(=O)OBr XFEIRVZQVUQECX-UHFFFAOYSA-N 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 1
- IRWYXBKJLQPPHF-UHFFFAOYSA-N carbonic acid ethenyl hydrogen carbonate Chemical compound OC(O)=O.OC(=O)OC=C IRWYXBKJLQPPHF-UHFFFAOYSA-N 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- FOCAUTSVDIKZOP-UHFFFAOYSA-M chloroacetate Chemical compound [O-]C(=O)CCl FOCAUTSVDIKZOP-UHFFFAOYSA-M 0.000 description 1
- 229940089960 chloroacetate Drugs 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 125000000490 cinnamyl group Chemical group C(C=CC1=CC=CC=C1)* 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- LDHQCZJRKDOVOX-NSCUHMNNSA-N crotonic acid Chemical compound C\C=C\C(O)=O LDHQCZJRKDOVOX-NSCUHMNNSA-N 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000012866 crystallographic experiment Methods 0.000 description 1
- FNIATMYXUPOJRW-UHFFFAOYSA-N cyclohexylidene Chemical group [C]1CCCCC1 FNIATMYXUPOJRW-UHFFFAOYSA-N 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 125000002576 diazepinyl group Chemical group N1N=C(C=CC=C1)* 0.000 description 1
- PIZLBWGMERQCOC-UHFFFAOYSA-N dibenzyl carbonate Chemical compound C=1C=CC=CC=1COC(=O)OCC1=CC=CC=C1 PIZLBWGMERQCOC-UHFFFAOYSA-N 0.000 description 1
- 229940120124 dichloroacetate Drugs 0.000 description 1
- JXTHNDFMNIQAHM-UHFFFAOYSA-N dichloroacetic acid Chemical compound OC(=O)C(Cl)Cl JXTHNDFMNIQAHM-UHFFFAOYSA-N 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 1
- 125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 description 1
- 125000005057 dihydrothienyl group Chemical group S1C(CC=C1)* 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 description 1
- 108010057167 dimethylaniline monooxygenase (N-oxide forming) Proteins 0.000 description 1
- ZXSBDSGRQIWJPM-UHFFFAOYSA-N dimethylcarbamothioic s-acid Chemical compound CN(C)C(S)=O ZXSBDSGRQIWJPM-UHFFFAOYSA-N 0.000 description 1
- 125000000532 dioxanyl group Chemical group 0.000 description 1
- 125000005982 diphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 125000005883 dithianyl group Chemical group 0.000 description 1
- 125000005411 dithiolanyl group Chemical group S1SC(CC1)* 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- PAVZHTXVORCEHP-UHFFFAOYSA-N ethylboronic acid Chemical compound CCB(O)O PAVZHTXVORCEHP-UHFFFAOYSA-N 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003495 flagella Anatomy 0.000 description 1
- FGIVSGPRGVABAB-UHFFFAOYSA-N fluoren-9-ylmethyl hydrogen carbonate Chemical compound C1=CC=C2C(COC(=O)O)C3=CC=CC=C3C2=C1 FGIVSGPRGVABAB-UHFFFAOYSA-N 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000010436 fluorite Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- QEWYKACRFQMRMB-UHFFFAOYSA-N fluoroacetic acid Chemical compound OC(=O)CF QEWYKACRFQMRMB-UHFFFAOYSA-N 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 239000012520 frozen sample Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 238000007306 functionalization reaction Methods 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229960001867 guaiacol Drugs 0.000 description 1
- 125000006277 halobenzyl group Chemical group 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- DOUHZFSGSXMPIE-UHFFFAOYSA-N hydroxidooxidosulfur(.) Chemical compound [O]SO DOUHZFSGSXMPIE-UHFFFAOYSA-N 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- WNZQDUSMALZDQF-UHFFFAOYSA-N isobenzofuranone Natural products C1=CC=C2C(=O)OCC2=C1 WNZQDUSMALZDQF-UHFFFAOYSA-N 0.000 description 1
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 1
- 238000010829 isocratic elution Methods 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 125000000654 isopropylidene group Chemical group C(C)(C)=* 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 229940058352 levulinate Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 208000035278 mandibuloacral dysplasia progeroid syndrome Diseases 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 231100000682 maximum tolerated dose Toxicity 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- TUDYPXFSYJRWDP-UHFFFAOYSA-N methoxy methyl carbonate Chemical compound COOC(=O)OC TUDYPXFSYJRWDP-UHFFFAOYSA-N 0.000 description 1
- RMIODHQZRUFFFF-UHFFFAOYSA-M methoxyacetate Chemical compound COCC([O-])=O RMIODHQZRUFFFF-UHFFFAOYSA-M 0.000 description 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
- 229940102396 methyl bromide Drugs 0.000 description 1
- CXHHBNMLPJOKQD-UHFFFAOYSA-M methyl carbonate Chemical compound COC([O-])=O CXHHBNMLPJOKQD-UHFFFAOYSA-M 0.000 description 1
- OIRDBPQYVWXNSJ-UHFFFAOYSA-N methyl trifluoromethansulfonate Chemical compound COS(=O)(=O)C(F)(F)F OIRDBPQYVWXNSJ-UHFFFAOYSA-N 0.000 description 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- KTMKRRPZPWUYKK-UHFFFAOYSA-N methylboronic acid Chemical compound CB(O)O KTMKRRPZPWUYKK-UHFFFAOYSA-N 0.000 description 1
- NYEBKUUITGFJAK-UHFFFAOYSA-N methylsulfanylmethanethioic s-acid Chemical compound CSC(O)=S NYEBKUUITGFJAK-UHFFFAOYSA-N 0.000 description 1
- 125000004092 methylthiomethyl group Chemical group [H]C([H])([H])SC([H])([H])* 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 238000005065 mining Methods 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- XWFDVJNZERXRSB-UHFFFAOYSA-N n-[[6-(2,3-dimethoxypropyl)-5,5-dimethyl-4-oxooxan-2-yl]-methoxymethyl]-2-hydroxy-2-(2-methoxy-5,6-dimethyl-4-methylideneoxan-2-yl)acetamide Chemical compound C1C(=O)C(C)(C)C(CC(COC)OC)OC1C(OC)NC(=O)C(O)C1(OC)OC(C)C(C)C(=C)C1 XWFDVJNZERXRSB-UHFFFAOYSA-N 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- FZIONDGWZAKCEX-UHFFFAOYSA-N nitrogen triiodide Chemical compound IN(I)I FZIONDGWZAKCEX-UHFFFAOYSA-N 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- JZJGRRJQAFIIKK-UHFFFAOYSA-N onnamide E Natural products C1C(O)C(C)(C)C(CC(=O)CCCC=CC=CC=CC(=O)NC(CCCN=C(N)N)C(O)=O)OC1CNC(=O)C(O)C1(OC)CC(=C)C(C)C(C)O1 JZJGRRJQAFIIKK-UHFFFAOYSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000006213 oxygenation reaction Methods 0.000 description 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
- 125000006505 p-cyanobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C#N)C([H])([H])* 0.000 description 1
- 125000006503 p-nitrobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1[N+]([O-])=O)C([H])([H])* 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 101150006864 ped gene Proteins 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- HVAMZGADVCBITI-UHFFFAOYSA-M pent-4-enoate Chemical compound [O-]C(=O)CCC=C HVAMZGADVCBITI-UHFFFAOYSA-M 0.000 description 1
- RGSFGYAAUTVSQA-UHFFFAOYSA-N pentamethylene Natural products C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- HBROIXGCFOMZHG-UHFFFAOYSA-N phenacyl hydrogen carbonate Chemical compound OC(=O)OCC(=O)C1=CC=CC=C1 HBROIXGCFOMZHG-UHFFFAOYSA-N 0.000 description 1
- 125000005561 phenanthryl group Chemical group 0.000 description 1
- ICFJFFQQTFMIBG-UHFFFAOYSA-N phenformin Chemical compound NC(=N)NC(=N)NCCC1=CC=CC=C1 ICFJFFQQTFMIBG-UHFFFAOYSA-N 0.000 description 1
- DKTXXUNXVCHYDO-UHFFFAOYSA-N phenoxyborinic acid Chemical compound OBOC1=CC=CC=C1 DKTXXUNXVCHYDO-UHFFFAOYSA-N 0.000 description 1
- PWXJULSLLONQHY-UHFFFAOYSA-N phenylcarbamic acid Chemical compound OC(=O)NC1=CC=CC=C1 PWXJULSLLONQHY-UHFFFAOYSA-N 0.000 description 1
- FAQJJMHZNSSFSM-UHFFFAOYSA-N phenylglyoxylic acid Chemical compound OC(=O)C(=O)C1=CC=CC=C1 FAQJJMHZNSSFSM-UHFFFAOYSA-N 0.000 description 1
- NIXKBAZVOQAHGC-UHFFFAOYSA-N phenylmethanesulfonic acid Chemical compound OS(=O)(=O)CC1=CC=CC=C1 NIXKBAZVOQAHGC-UHFFFAOYSA-N 0.000 description 1
- XMGMFRIEKMMMSU-UHFFFAOYSA-N phenylmethylbenzene Chemical group C=1C=CC=CC=1[C]C1=CC=CC=C1 XMGMFRIEKMMMSU-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- SIOXPEMLGUPBBT-UHFFFAOYSA-M picolinate Chemical compound [O-]C(=O)C1=CC=CC=N1 SIOXPEMLGUPBBT-UHFFFAOYSA-M 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000005936 piperidyl group Chemical group 0.000 description 1
- 125000005547 pivalate group Chemical group 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 229930001119 polyketide Natural products 0.000 description 1
- 150000003881 polyketide derivatives Chemical class 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 125000001844 prenyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000013587 production medium Substances 0.000 description 1
- KTZUEEIBRDOPPX-UHFFFAOYSA-N prop-2-ynyl hydrogen carbonate Chemical compound OC(=O)OCC#C KTZUEEIBRDOPPX-UHFFFAOYSA-N 0.000 description 1
- 125000001325 propanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000002755 pyrazolinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- LHGVFZTZFXWLCP-UHFFFAOYSA-N pyrocatechol monomethyl ether Natural products COC1=CC=CC=C1O LHGVFZTZFXWLCP-UHFFFAOYSA-N 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 239000013535 sea water Substances 0.000 description 1
- 230000024053 secondary metabolic process Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 238000007614 solvation Methods 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000000707 stereoselective effect Effects 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000005556 structure-activity relationship Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- 125000004646 sulfenyl group Chemical group S(*)* 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- XKXIQBVKMABYQJ-UHFFFAOYSA-M tert-butyl carbonate Chemical compound CC(C)(C)OC([O-])=O XKXIQBVKMABYQJ-UHFFFAOYSA-M 0.000 description 1
- ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical group C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000005958 tetrahydrothienyl group Chemical group 0.000 description 1
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 125000005308 thiazepinyl group Chemical group S1N=C(C=CC=C1)* 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000002053 thietanyl group Chemical group 0.000 description 1
- 238000006177 thiolation reaction Methods 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- UIERETOOQGIECD-ONEGZZNKSA-N tiglic acid Chemical compound C\C=C(/C)C(O)=O UIERETOOQGIECD-ONEGZZNKSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000001551 total correlation spectroscopy Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 238000004627 transmission electron microscopy Methods 0.000 description 1
- ILJSQTXMGCGYMG-UHFFFAOYSA-N triacetic acid Chemical compound CC(=O)CC(=O)CC(O)=O ILJSQTXMGCGYMG-UHFFFAOYSA-N 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229910052722 tritium Chemical group 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 125000001834 xanthenyl group Chemical group C1=CC=CC=2OC3=CC=CC=C3C(C12)* 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/02—Oxygen as only ring hetero atoms
- C12P17/06—Oxygen as only ring hetero atoms containing a six-membered hetero ring, e.g. fluorescein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/07—Bacillus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/185—Escherichia
- C12R2001/19—Escherichia coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/38—Pseudomonas
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/465—Streptomyces
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrane Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
R1、R2、及びR3は、水素、置換又は非置換C1〜C12アルキル、置換又は非置換C2〜C12アルケニル、置換又は非置換C2〜C12アルキニル、-C(=O)Ra、-C(=O)ORb及び-(C=O)NRcRdからそれぞれ独立して選択され;
R4は、水素、-C(=O)Ra、-C(=O)ORb、及び-C(=O)NRcRdから選択され;
Raは、水素、置換又は非置換C1〜C12アルキル、置換又は非置換C2〜C12アルケニル、置換又は非置換C2〜C12アルキニル、アリール及びヘテロシクリルから選択され;
Rbは、置換又は非置換C1〜C12アルキル、置換又は非置換C2〜C12アルケニル、置換又は非置換C2〜C12アルキニル、アリール及びヘテロシクリルから選択され;
Rc及びRdは、水素、置換又は非置換C1〜C12アルキル、置換又は非置換C2〜C12アルケニル、置換又は非置換C2〜C12アルキニル、アリール及びヘテロシクリルから独立して選択され;
ただし、R1及びR2は、同時にメチルではない)
に関する。
R1、R2、及びR3は、水素、置換又は非置換C1〜C12アルキル、置換又は非置換C2〜C12アルケニル、置換又は非置換C2〜C12アルキニル、-C(=O)Ra、-C(=O)ORb及び-(C=O)NRcRdからそれぞれ独立して選択され;
R4は、水素、-C(=O)Ra、-C(=O)ORb、及び-C(=O)NRcRdから選択され;
Raは、水素、置換又は非置換C1〜C12アルキル、置換又は非置換C2〜C12アルケニル、置換又は非置換C2〜C12アルキニル、アリール及びヘテロシクリルから選択され;
Rbは、置換又は非置換C1〜C12アルキル、置換又は非置換C2〜C12アルケニル、置換又は非置換C2〜C12アルキニル、アリール及びヘテロシクリルから選択され;
Rc及びRdは、水素、置換又は非置換C1〜C12アルキル、置換又は非置換C2〜C12アルケニル、置換又は非置換C2〜C12アルキニル、アリール及びヘテロシクリルから独立して選択される)
を得る方法であって、
- 野生型海洋細菌株PHM005又はその変異体を適切な条件下で培養して式:
- 化合物1又は2を単離する工程;及び、必要に応じて、
- 化合物1又は2を誘導体化する工程
を含む方法に関する。
- PHM005の変異体又は組換え型宿主細胞又はトランスジェニック生物をLab生合成遺伝子クラスターを発現させる条件下で培養する工程;及び
- 生成されたペデリン様及び/又はオンナミド様化合物を単離する工程
を含む方法に関する。
本願において言及される配列は、添付の配列リストに記載されている。これらの配列を下記に簡単に要約する:
配列番号1 ラブレンジア属PHM005の16S rRNA遺伝子の配列(1355bp)。
配列番号2 Lab生合成遺伝子クラスターの核酸配列。
配列番号3 Lab706推定アシル担体タンパク質のタンパク質配列。
配列番号4 Lab707推定HMGSのタンパク質配列。
配列番号5 Lab708PKSのタンパク質配列。
配列番号6 Lab709TransAT PKSのタンパク質配列。
配列番号7 Lab710推定アシル担体タンパク質のタンパク質配列。
配列番号8 Lab711推定FADオキシゲナーゼのタンパク質配列。
配列番号9 Lab712推定o-メチルトランスフェラーゼのタンパク質配列。
配列番号10 Lab713推定シトクロムP450のタンパク質配列。
配列番号11 Lab714推定マロニルCoA-ACPトランスアシラーゼ又はFMTオキシドレダクターゼのタンパク質配列。
配列番号12 Lab715推定マロニルCoA-ACPトランスアシラーゼ又はアシルトランスフェラーゼのタンパク質配列。
配列番号13 Lab716マロニルCoA-ACPトランスアシラーゼのタンパク質配列。
配列番号14 Lab717エノイル-CoAヒドラターゼのタンパク質配列。
配列番号15 Lab718ベータ-ケトアシルシンテターゼのタンパク質配列。
配列番号16 Lab719TransAT PKS/NRPSのタンパク質配列。
配列番号17 Lab720推定FADモノオキシゲナーゼのタンパク質配列。
配列番号18 TransAT PKSの一部であるLab721のタンパク質配列。
配列番号19 TransAT PKSの一部であるLab722のタンパク質配列。
配列番号20 PKSの一部であるLab723のタンパク質配列。
配列番号21 TransAT PKS/NRPSの一部であるLab724のタンパク質配列。
配列番号22 PKSの一部であるLab725のタンパク質配列。
配列番号23 Lab726推定o-メチルトランスフェラーゼのタンパク質配列。
キシベンジリデンオルトエステル、1-(N,N-ジメチルアミノ)エチリデン誘導体、α-(N,N-ジメチルアミノ)ベンジリデン誘導体、ブタン2-3-ビスアセタール(BBA)、シクロヘキサン-1,2-ジアセタール(CDA)、及びジスピロケタールが挙げられる。シリル誘導体の例としては、ジ-t-ブチルシリレン基(DTBS(OR)2)、1-(シクロヘキシル)-1-(メチル)シリレン(Cy)(Me)Si(OR)2、ジ-イソプロピルシリレン(i-プロピル)2Si(OR)2、ジシクロヘキシルシリレン(Cy)2Si(OR)2、1,3-(1,1,3,3-テトライソプロピルジシロキサニリデン)誘導体(TIPDS(OR)2)、1,1,3,3-テトラ-t-ブトキシジシロキサニリデン誘導体(TBDS(OR)2)、メチレン-ビス-(ジイソプロピルシラノキサニリデン)(MDPS(OR)2)、及び1,1,4,4-テトラフェニル-1,4-ジシラニリデン(SIBA(OR)2)が挙げられる。環状ボロナートの例としては、メチルボロナート、エチルボロナート、フェニルボロナート、及びo-アセトアミドフェニルボロナートが挙げられる。
を更に有する化合物である。
(式中、R1、R2、R3及びR4は、一般式IIにおいて先に規定の通りである)
を更に有する化合物を製造する方法である。
- 保護された二次OHの存在下で保護された一次OHから選択的に除去されるのに好適な-OHのための保護基で化合物1'中の全てのヒドロキシ基を保護すること。そうした保護基の例としては、トリメチルシリル、トリエチルシリル、トリイソプロピルシリル及びtert-ブチルジメチルシリルが挙げられる。この工程に最も好ましい保護基は、tert-ブチルジメチルシリルである;
- 一次OH保護基を選択的に除去すること;
- 結果として得られる一次ヒドロキシ基を好適なメチル化試薬でメチル化すること;及び
- 他のOHのための保護基を除去すること
によって得られる。
- 1,2-ジオール基を1,2-ジオールのための好適な保護基で保護すること。1,2-ジオールのための適切な保護基の例としては、対応する1,2-ジオールとの反応後にモクデン(Mocdene)アセタール、ボクデン(Bocdene)アセタール、アクロレインアセタール、ベンジリデンアセタール、(t-ブチルジメチルシリルオキシ)ベンジリデンアセタール、メシチレンアセタール、メトキシメチレンアセタール、エトキシメチレンアセタール、環状カルボナート、メチルボロナート及びエチルボロナートを生成する基が挙げられるが、これに限定されない。この工程により好ましい保護基は、モクデンアセタール、ボクデンアセタール、ベンジリデンアセタール及び環状カルボナートを生成するものであり、ベンジリデンアセタールを生成する保護基が最も好ましい;
- 他のヒドロキシ基を前工程の1,2-ジオール保護基と直交する-OHのための保護基で保護すること。この工程に好適なOHのための保護基の例は、トリメチルシリル、トリエチルシリル、トリイソプロピルシリルtert-ブチルジメチルシリル、及びアセチルである。この工程に最も好ましい保護基は、tert-ブチルジメチルシリル及びアセチルである;
- 1,2-ジオール保護基を除去すること;
- 結果として得られる1,2-ジオールを好適なメチル化試薬でメチル化すること;及び
- 他のOHのための保護基を除去すること
によって得られる。
配列番号2に示すヌクレオチド配列;又は
配列番号2の相補体であるヌクレオチド配列;又は
高度にストリンジェントな条件下で配列番号2若しくはその相補体にハイブリダイズするヌクレオチド配列;又は
配列番号2若しくはその相補体に対して少なくとも80%の配列同一性を有するヌクレオチド配列
を含む。
細菌単離
ペデリン型産生細菌、ラブレンジア属PHM005を、2005年にケニア沖の着生性の高い未確認のサンゴ海綿生息地から18mの深さで収集した堆積物サンプルから単離した。およそ5グラムの海砂利材料を滅菌人工海水(ASW)を含有する50mlのファルコンチューブに収集し、5日間5℃に維持してから処理した。実験室に入れた後、サンプルを均質化し、ASWでの1:100希釈物100μlを、27g/Lの海洋塩(Tropic Marin(登録商標)PRO-REEF)、16g/Lの寒天及び0.2mg/mLのシクロヘキシミドからなる海塩培地と共に直接ペトリ皿に広げた。3週間28℃でインキュベートした後、わずかに褐色のコロニーを選び、同じ海塩培地に移して純度を確認し、分子特性評価用のバイオマスを生成し、更に細胞バンクとして20%グリセロールで-80℃で保存するために1つのコロニーを液体海洋ブロスに接種した。
電子顕微鏡法。
中期指数増殖期の細胞を400メッシュの炭素-コロジオンコーティングしたグリッドに2分間吸着させ、2%酢酸ウラニルでネガティブ染色し、100kVで作動するJeol社JEM1011透過型電子顕微鏡で画像化し、CCDのGatan社ErlangshenES1000Wカメラで撮影した。
16S rRNAの特性評価。
DNA抽出のため、菌株を海洋ブロス(DIFCO 1196)中で72時間増殖させた。細胞を回収し、4%NP40で10分間煮沸することにより溶解させた。細胞残屑を遠心分離により廃棄した。16S rDNA遺伝子を、細菌プライマF1及びR5を使用したポリメラーゼ連鎖反応により増幅させた。系統樹(図2)は、ペアワイズアラインメントベースの類似度係数とBioNumerics V7.5(Applied Maths社)を使用したクラスター分析用のUPGMAによって生成した。系統発生的近隣を同定し、SILVA LTPs123データベースとの比較によりペアワイズ16S rDNA遺伝子配列の類似性を計算した。
培養及び抽出。
菌株は、増殖するために明らかに海洋塩を必要とする。培養後、全ブロスを凍結乾燥し、有機溶媒の混合物で抽出し、粗抽出物の0.5mLサンプルを乾燥させ、細胞毒性活性についてスクリーニングした。最高の細胞毒性活性は、120時間で16B/d培地において達成された。この培地は、17.5g/Lの醸造用酵母(Sensient社、G2025)、76g/Lのマンニトール、7g/Lの(NH4)2SO4、13g/LのCaCO3、0.09g/LのFeCl3及び36g/Lの海洋塩(Tropic Marin(登録商標)PRO-REEF)からなっていた。16B/d培地におけるこの細菌の50Lのスケールアップを、それぞれ作業容量が250mLの200×2Lの三角フラスコで調製した。別の高度に増殖させた前接種材料から海洋ブロス(DIFCO 1196)中で72時間増殖させた細菌の2%を生産用フラスコに接種した。スケールアップは、5cm偏心の220rpmの回転式振とう機で、28℃で120時間インキュベートした。次いで、培養物を6,000rpmで20分間遠心分離し、45Lの水性上清を得、これをEtOAcで2回抽出し、有機相を乾燥させて粗抽出物(1.8g)を得た。
化合物1の単離。
抽出物をシリカゲルVFC(真空フラッシュクロマトグラフィー)システムに適用し、n-ヘキサン-EtOAcとEtOAc-MeOHの混合物での段階的勾配溶離を使用して11の画分を得た。活性画分をEtOAcとEtOAc-MeOHの9:1(550.0mg)で溶出し、13.5mL/分の流量にて30分かけてSymmetry C18カラム(19×150mm、7μm)とCH3CNが5%〜35%のH2O/CH3CNの直線勾配を使用した分取逆相HPLCに供し、保持時間24.5分でHPLC-MSクロマトグラムに基づく1を含有する非常に活性のあるピーク画分(77.0mg)を得た。この画分を更にXBridge C18カラム(10×250mm、5μm)でのセミ分取HPLCと流量4mL/分でのH2O/CH3CN(78:22)による定組成溶離により精製し、これらのHPLC条件での保持時間25.0分で、24.5mgの純粋な化合物1を得た。
化合物2の単離
化合物2を、海洋由来菌株PHM005の発酵ブロス(15L)の全ブロス粗抽出物(9.5g)から単離した。抽出物をn-ヘキサン-EtOAcとEtOAc-MeOHの混合物での段階的勾配溶離を使用したシリカゲルVFC(真空フラッシュクロマトグラフィー)システムに適用し、7つの画分を得た。化合物2を含有する活性画分をEtOAc-MeOH4:1(659.0mg)で溶出し、CH3CNが5%〜60%のH2O/CH3CNの直線勾配を使用して、Symmetry C18カラム(7.8×150mm、5μm)を備えたセミ分取逆相HPLCに流量3.0mL/分にて25分供し、25〜30分の間にHPLC-MSクロマトグラムに基づく化合物2を含有する非常に活性のある時間画分(time-fraction)(28.0mg)を得た。この画分を、CH3CNが20%〜30%のH2O/CH3CNの直線勾配を使用して、Symmetry C18カラム(7.8×150mm、5μm)で再度セミ分取HPLCにより流量2.5mL/分にて20分で精製し、これらのHPLC条件での保持時間11.5分で、2.6mgの純粋な化合物2を得た。
化合物3の合成
窒素雰囲気下、1(2.5mg、5.1μmol)の乾燥DCM(2mL)溶液に、ピリジン(10μL、124μmol)、DMAP(触媒量)及びAc2O(2.9μL、31mmol)を添加した。反応物を室温で一晩放置した。混合物を真空下で濃縮し、シリカゲル(n-ヘキサン/EtOAc1:1)上でのフラッシュカラムクロマトグラフィーにより精製して、3(3mg、95%)を白色固体として得た。
抗腫瘍活性の検出のためのin vitroバイオアッセイ
このアッセイの目的は、試験対象のサンプルのin vitro細胞増殖抑制(腫瘍細胞の増殖を遅延若しくは停止させる能力)又は細胞毒性(腫瘍細胞を殺す能力)活性を評価することである。
スルホローダミンB(SRB)反応を使用した比色分析アッセイを、細胞増殖及び生存率を定量的に測定するために適用した(Skehanら、J. Natl. Cancer Inst. 1990, 82, 1107〜1112頁が記載する技法に従った)。
Claims (32)
- 一般式Iの化合物、又はその薬学的に許容される塩、互変異性体若しくは立体異性体
R1、R2、及びR3は、水素、置換又は非置換C1〜C12アルキル、置換又は非置換C2〜C12アルケニル、置換又は非置換C2〜C12アルキニル、-C(=O)Ra、-C(=O)ORb及び-(C=O)NRcRdからそれぞれ独立して選択され;
R4は、水素、-C(=O)Ra、-C(=O)ORb、及び-C(=O)NRcRdから選択され;
Raは、水素、置換又は非置換C1〜C12アルキル、置換又は非置換C2〜C12アルケニル、置換又は非置換C2〜C12アルキニル、アリール及びヘテロシクリルから選択され;
Rbは、置換又は非置換C1〜C12アルキル、置換又は非置換C2〜C12アルケニル、置換又は非置換C2〜C12アルキニル、アリール及びヘテロシクリルから選択され;
Rc及びRdは、水素、置換又は非置換C1〜C12アルキル、置換又は非置換C2〜C12アルケニル、置換又は非置換C2〜C12アルキニル、アリール及びヘテロシクリルから独立して選択され;
ただし、R1及びR2は、同時にメチルではない)。 - 一般式III、又はその薬学的に許容される塩、互変異性体若しくは立体異性体
を更に有する請求項1に記載の化合物。 - R1が、水素及び置換又は非置換C1〜C6アルキルから選択される、請求項1又は2に記載の化合物。
- R1が、水素及びメチルから選択される、請求項3に記載の化合物。
- R2が、水素及び-C(=O)Raから選択され、ここで、Raは、置換又は非置換C1〜C6アルキルから選択される、請求項1から4のいずれか一項に記載の化合物。
- R2が、水素及びアセチルから選択される、請求項5に記載の化合物。
- R3及びR4が、水素及び-C(=O)Raから独立して選択され、ここで、それぞれの出現におけるRaは、置換又は非置換C1〜C6アルキルから独立して選択される、請求項1から6のいずれか一項に記載の化合物。
- R3及びR4が、水素及びアセチルから独立して選択される、請求項7に記載の化合物。
- 式:
- 式:
- 請求項1から10のいずれか一項に記載の化合物、又はその薬学的に許容される塩、互変異性体若しくは立体異性体と、薬学的に許容される担体又は希釈剤とを含む医薬組成物。
- 医薬として使用するための、請求項1から10のいずれか一項に記載の化合物、又はその薬学的に許容される塩、互変異性体若しくは立体異性体、又は請求項11に記載の組成物。
- がんの治療用の医薬として使用するための、請求項12に記載の化合物又は組成物。
- 前記がんの治療用の医薬の調製における、請求項1から10のいずれか一項に記載の化合物、又はその薬学的に許容される塩、互変異性体若しくは立体異性体の使用。
- がんに罹患した患者、とりわけヒトを治療する方法であって、請求項1から10のいずれか一項に記載の化合物、又はその薬学的に許容される塩、互変異性体若しくは立体異性体の治療効果のある量の投与を、それを必要とする罹患個体に行うことを含む、方法。
- 式IIの化合物、又はその薬学的に許容される塩、互変異性体若しくは立体異性体
- R1、R2、及びR3は、水素、置換又は非置換C1〜C12アルキル、置換又は非置換C2〜C12アルケニル、置換又は非置換C2〜C12アルキニル、-C(=O)Ra、-C(=O)ORb及び-(C=O)NRcRdからそれぞれ独立して選択され;
- R4は、水素、-C(=O)Ra、-C(=O)ORb、及び-C(=O)NRcRdから選択され;
- Raは、水素、置換又は非置換C1〜C12アルキル、置換又は非置換C2〜C12アルケニル、置換又は非置換C2〜C12アルキニル、アリール及びヘテロシクリルから選択され;
- Rbは、置換又は非置換C1〜C12アルキル、置換又は非置換C2〜C12アルケニル、置換又は非置換C2〜C12アルキニル、アリール及びヘテロシクリルから選択され;
- Rc及びRdは、水素、置換又は非置換C1〜C12アルキル、置換又は非置換C2〜C12アルケニル、置換又は非置換C2〜C12アルキニル、アリール及びヘテロシクリルから独立して選択される)
を得る方法であって、
- 野生型海洋細菌株PHM005又はその変異体を適切な条件下で培養して式:
- 化合物1又は2を単離する工程;及び、必要に応じて、
- 化合物1又は2を誘導体化する工程
を含む、方法。 - 式IIの前記化合物が式IV
(式中、R1、R2、R3、及びR4は、式IIについて請求項16に規定の通りである)
を更に有する化合物である、請求項16に記載の方法。 - スペインバレンシア大学のColeccion Espanola de Cultivos Tipoに受託番号CECT-9225で寄託された、生物学的に純粋な菌株PHM005。
- ラブレンジア属、特に菌株PHM005に由来する、Lab生合成遺伝子クラスターを含む、又は前記Lab生合成遺伝子クラスターを含む配列に相補的である、単離された核酸。
- 配列番号2に示すヌクレオチド配列;又は
配列番号2の相補体であるヌクレオチド配列;又は
高度にストリンジェントな条件下で配列番号2若しくはその相補体にハイブリダイズするヌクレオチド配列;又は
配列番号2若しくはその相補体に対して少なくとも80%の配列同一性を有するヌクレオチド配列
を含む、請求項19に記載の単離されたヌクレオチド配列。 - 図3に示すように、Lab生合成遺伝子クラスターの個々のユニット及び/又はモジュールを形成する核酸断片を含む、単離された核酸。
- 請求項19から21のいずれか一項に記載の核酸配列によってコード化されたモジュール型酵素系。
- 配列番号3〜配列番号23の配列によって形成される群から選択されるタンパク質配列、又はこれらの配列に対して少なくとも80%の配列同一性を有するタンパク質配列の1つ又は複数を含む、請求項22に記載のモジュール型酵素系。
- ペデリン様若しくはオンナミド様化合物及び/又はポリケチド部分及び/又は非リボソームペプチド部分の合成において機能活性を有する、請求項22又は23に記載のモジュール型酵素系。
- ラブレンジア属、特に菌株PHM005に由来するLab生合成遺伝子クラスターから本質的になる核酸を含むベクター。
- 請求項19から21のいずれか一項に記載の核酸配列を含むベクター。
- 請求項19から21のいずれか一項に記載の核酸を含む、又は請求項25若しくは26に記載のベクターを含有する、組換え型宿主細胞又はトランスジェニック生物。
- 細菌細胞、特にシュードモナス、アシネトバクター、バシラス、ストレプトミセス又は大腸菌の細胞である、請求項27に記載の組換え型宿主細胞。
- PHM005の変異体又は請求項27に記載の組換え型宿主細胞又は請求項28に規定のトランスジェニック生物を使用してペデリン様又はオンナミド様化合物を生成する方法であって、:
- 前記PHM005の変異体又は前記組換え型宿主細胞又は前記トランスジェニック生物を前記Lab生合成遺伝子クラスターを発現させる条件下で培養する工程;及び
- 生成されたペデリン様又はオンナミド様化合物を単離する工程
を含む、方法。 - lab719の生成物を発現させてオンナミド様化合物を提供する、請求項29に記載の方法。
- 改変Lab生合成遺伝子クラスターの調製における請求項19から21のいずれか一項に記載の核酸の使用。
- ペデリン様化合物の調製における請求項19から21のいずれか一項に記載の核酸の使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17382140.6 | 2017-03-17 | ||
EP17382140 | 2017-03-17 | ||
PCT/EP2018/056665 WO2018167270A1 (en) | 2017-03-17 | 2018-03-16 | Anticancer compounds |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2020510065A true JP2020510065A (ja) | 2020-04-02 |
JP2020510065A5 JP2020510065A5 (ja) | 2021-04-30 |
JP7209633B2 JP7209633B2 (ja) | 2023-01-20 |
Family
ID=58398130
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019550649A Active JP7209633B2 (ja) | 2017-03-17 | 2018-03-16 | 抗がん化合物 |
Country Status (17)
Country | Link |
---|---|
US (1) | US20210317490A1 (ja) |
EP (1) | EP3596068A1 (ja) |
JP (1) | JP7209633B2 (ja) |
KR (1) | KR102547649B1 (ja) |
CN (1) | CN110650954B (ja) |
AU (2) | AU2018235140B2 (ja) |
BR (1) | BR112019019301A2 (ja) |
CA (1) | CA3056725A1 (ja) |
CL (2) | CL2019002661A1 (ja) |
IL (2) | IL292572A (ja) |
MA (1) | MA49880A (ja) |
MX (2) | MX2019010890A (ja) |
MY (1) | MY195435A (ja) |
SG (1) | SG11201908267XA (ja) |
UA (1) | UA126338C2 (ja) |
WO (1) | WO2018167270A1 (ja) |
ZA (2) | ZA201906518B (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114615999B (zh) * | 2019-09-05 | 2024-03-08 | 法马马有限公司 | 药物抗体偶联物 |
CN112661808B (zh) * | 2020-12-23 | 2022-05-27 | 浙江大学 | 一种酯肽类化合物及其制备方法和应用 |
EP4326869A1 (en) * | 2021-04-20 | 2024-02-28 | University of Louisville | Recombinant miropin |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20140161877A1 (en) * | 2011-07-22 | 2014-06-12 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Pederin and psymberin agents |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0289203B1 (en) | 1987-04-29 | 1992-01-08 | Harbor Branch Oceanographic Institution, Inc. | Antitumor and antiviral compounds of marine origin |
US4801606A (en) | 1987-07-17 | 1989-01-31 | Harbor Branch Oceanographic Institution Inc. | Antiviral compositions |
WO2003044186A2 (en) | 2001-11-22 | 2003-05-30 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Novel gene cluster of pederin biosynthesis genes |
-
2018
- 2018-03-16 BR BR112019019301A patent/BR112019019301A2/pt unknown
- 2018-03-16 EP EP18711108.3A patent/EP3596068A1/en active Pending
- 2018-03-16 MA MA049880A patent/MA49880A/fr unknown
- 2018-03-16 UA UAA201910399A patent/UA126338C2/uk unknown
- 2018-03-16 WO PCT/EP2018/056665 patent/WO2018167270A1/en active Application Filing
- 2018-03-16 MY MYPI2019005105A patent/MY195435A/en unknown
- 2018-03-16 KR KR1020197030504A patent/KR102547649B1/ko active IP Right Grant
- 2018-03-16 JP JP2019550649A patent/JP7209633B2/ja active Active
- 2018-03-16 CN CN201880018986.1A patent/CN110650954B/zh active Active
- 2018-03-16 AU AU2018235140A patent/AU2018235140B2/en active Active
- 2018-03-16 IL IL292572A patent/IL292572A/en unknown
- 2018-03-16 US US16/494,720 patent/US20210317490A1/en active Pending
- 2018-03-16 SG SG11201908267X patent/SG11201908267XA/en unknown
- 2018-03-16 MX MX2019010890A patent/MX2019010890A/es unknown
- 2018-03-16 CA CA3056725A patent/CA3056725A1/en active Pending
-
2019
- 2019-09-12 MX MX2021011385A patent/MX2021011385A/es unknown
- 2019-09-15 IL IL269353A patent/IL269353B/en unknown
- 2019-09-16 CL CL2019002661A patent/CL2019002661A1/es unknown
- 2019-10-03 ZA ZA2019/06518A patent/ZA201906518B/en unknown
-
2020
- 2020-10-05 ZA ZA2020/06147A patent/ZA202006147B/en unknown
-
2021
- 2021-01-14 CL CL2021000117A patent/CL2021000117A1/es unknown
- 2021-12-01 AU AU2021277683A patent/AU2021277683B2/en active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20140161877A1 (en) * | 2011-07-22 | 2014-06-12 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Pederin and psymberin agents |
Non-Patent Citations (2)
Title |
---|
NAKABACHI, A. ET AL.: "Defensive Bacteriome Symbiont with a Drastically Reduced Genome", CURRENT BIOLOGY, vol. 23, JPN6022015482, 2013, pages 1478 - 1484, XP028689491, ISSN: 0004865811, DOI: 10.1016/j.cub.2013.06.027 * |
WU, F. ET AL.: "Total Synthesis of Pederin and Analogs", ANGEWANDTE CHEMIE, INTERNATIONAL EDITION, vol. 50, JPN6022015485, 2011, pages 1131 - 1134, XP055469240, ISSN: 0004865810, DOI: 10.1002/anie.201006438 * |
Also Published As
Publication number | Publication date |
---|---|
JP7209633B2 (ja) | 2023-01-20 |
IL292572A (en) | 2022-06-01 |
MX2019010890A (es) | 2019-12-19 |
ZA201906518B (en) | 2021-01-27 |
MY195435A (en) | 2023-01-20 |
ZA202006147B (en) | 2023-03-29 |
UA126338C2 (uk) | 2022-09-21 |
KR102547649B1 (ko) | 2023-06-23 |
CL2021000117A1 (es) | 2021-07-30 |
US20210317490A1 (en) | 2021-10-14 |
CN110650954B (zh) | 2023-11-03 |
KR20190129950A (ko) | 2019-11-20 |
AU2018235140A1 (en) | 2019-10-03 |
AU2021277683A1 (en) | 2021-12-23 |
CN110650954A (zh) | 2020-01-03 |
CA3056725A1 (en) | 2018-09-20 |
BR112019019301A2 (pt) | 2020-04-28 |
MA49880A (fr) | 2020-06-24 |
AU2018235140B2 (en) | 2021-11-11 |
EP3596068A1 (en) | 2020-01-22 |
IL269353A (en) | 2019-11-28 |
WO2018167270A1 (en) | 2018-09-20 |
IL269353B (en) | 2022-06-01 |
RU2019132808A3 (ja) | 2021-10-04 |
AU2021277683B2 (en) | 2023-03-09 |
MX2021011385A (es) | 2021-10-13 |
CL2019002661A1 (es) | 2019-12-27 |
SG11201908267XA (en) | 2019-10-30 |
RU2019132808A (ru) | 2021-04-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2021277683B2 (en) | Anticancer Compounds | |
Smetanina et al. | Oxirapentyns B–D produced by a marine sediment-derived fungus Isaria felina (DC.) Fr | |
Chen et al. | Stereochemical determination of new cytochalasans from the plant endophytic fungus Trichoderma gamsii | |
Li et al. | Cytosporinols AC, new caryophyllene sesquiterpenoids from Cytospora sp. | |
US7423008B2 (en) | Derivatives of mithramycin and methods of making and uses thereof | |
RU2773023C2 (ru) | Противоопухолевые соединения | |
Phongsopitanun et al. | Marine Streptomyces chumphonensis KK1-2 T produces piericidin A1 as the major secondary metabolite. | |
Ohlendorf et al. | Phenylnannolones A–C: Biosynthesis of new secondary metabolites from the myxobacterium Nannocystis exedens | |
Uemura et al. | Drug Leads Derived from Japanese Marine Organisms | |
US20160185717A1 (en) | Compounds with antibacterial activity | |
US10414745B2 (en) | Phenol derivatives to treat cancer | |
US7626043B2 (en) | Antiproliferative activity of the leiodermatolide class of macrolides | |
US20090203775A1 (en) | Novel compound and a novel microorganism for producing the novel compound | |
JP5641716B2 (ja) | ストレプトミセス属に属する微生物が産生する新規化合物、その化合物を産生する微生物、及びその化合物を有効成分とする医薬製剤 | |
US20070111952A1 (en) | Glycosylated triketide delta lactones | |
Rémy et al. | Furanones and Anthranilic Acid Derivatives from the Endophytic Fungus Dendrothyrium variisporum | |
Elsayed et al. | Royal Netherlands Academy of Arts and Sciences (KNAW) | |
Yan et al. | Cytosporinols AC, new caryophyllene sesquiterpenoids from Cytospora sp. | |
Bannerman-Akwei | Synthesis of marine chemicals and derivatives as potential anti-cancer drugs | |
Lin | Isolation of secondary metabolites from Aspergillus nidulans |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20191115 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210316 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210316 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220425 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220725 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220905 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221110 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20221212 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20230110 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7209633 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |